Redox‐active injectable gel using polyion complex to achieve sustained release of exenatide and enhance therapeutic efficacy for the treatment of type 2 diabetes

2019 ◽  
Vol 107 (5) ◽  
pp. 1107-1113 ◽  
Author(s):  
Shiro Ishii ◽  
Sho Sakaue ◽  
Yukio Nagasaki
Keyword(s):  
Type 2 Diabetes ◽  
Sustained Release ◽  
Therapeutic Efficacy ◽  
Polyion Complex ◽  
Redox Active

scholarly journals Evaluation of the effect of MTNR1B rs10830963 gene polymorphism on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

2019 ◽  
Author(s):  
Jinfang Song ◽  
Mingzhu Zhang ◽  
Jiang Ni ◽  
Tao Wang ◽  
Yi-Qing Zhao
Keyword(s):  
Type 2 Diabetes ◽  
Gene Polymorphism ◽  
Therapeutic Efficacy ◽  
Healthy Subjects ◽  
Venous Blood ◽  
Melting Curve ◽  
Allelic Frequency ◽  
Model Assessment ◽  
Chinese Han

Abstract Background: Several studies have shown the association of polymorphisms in the MTNR1B gene with type 2 diabetes mellitus (T2DM). However, there is no evidence about the impacts of its genetic polymorphism on the therapeutic efficacy of nateglinide. Therefore, this prospective case-control study was designed to investigate the effect of MTNR1B rs10830963 gene polymorphism on the therapeutic efficacy of nateglinide in treating T2DM. Methods: We genotyped 200 healthy subjects using the method of the high resolution of melting curve (HRM). A total of 60 T2DM patients were enrolled and given nateglinide (360 mg/d) for 8 weeks orally who had the same genotypes CYP2C9*1 and SLCO1B1 521TT respectively. The outcome was measured by collecting the venous blood samples before and at the 8th week of the treatment. Also, anthropometric measurements, glucose, and lipid metabolism were determined before and after the nateglinide treatment. Results: It was found that the risk G allelic frequency of MTNR1B rs10830963 was higher in T2DM patients when compared with the healthy subjects (P<0.05). 60 newly diagnosed patients with type 2 diabetes after completing the eight weeks treatment came for the follow-up visit and showed a reduction in fasting plasma glucose (FPG) levels with an increase in homeostasis model assessment for β cell HOMA-β in the carriers of genotype CG + GG at rs10830963, when compared with the wild-type CC (P <0.05). Conclusion: Thus, it was found that the MTNR1B rs10830963 polymorphism was associated with the therapeutic efficacy of nateglinide in T2DM patients. Also, the CC homozygotes had a better effect than G allele carriers. Trial registration: This study was registered in the Chinese Clinical Trial Register (No. ChiCTR-CCC13003536).

Psychometric Properties of the Korean Version of the Perceived Therapeutic Efficacy Scale for Physical Activity in Adults With Type 2 Diabetes

2021 ◽  
pp. 263501062110586
Author(s):  
Moonsun Kim ◽  
Chun-Ja Kim ◽  
Dae Jung Kim ◽  
Elizabeth A. Schlenk
Keyword(s):  
Physical Activity ◽  
Type 2 Diabetes ◽  
Factor Analysis ◽  
Glycemic Control ◽  
Confirmatory Factor Analysis ◽  
Therapeutic Efficacy ◽  
Cronbach’S Alpha ◽  
Cronbach's Alpha ◽  
Confirmatory Factor

Purpose: The purpose of this study is to translate the Perceived Therapeutic Efficacy Scale (PTES) into Korean and investigate its validity and reliability. Methods: The authors conducted a cross-sectional survey using baseline data from a randomized controlled study to psychometrically validate the PTES-Korean (PTES-K) among 108 adults with type 2 diabetes from an outpatient clinic at a university-affiliated hospital in Korea. The original PTES was forward-translated and back-translated to ensure translation equivalence of the PTES-K. Structured questionnaires were used for psychometric evaluation; exploratory and confirmatory factor analysis assessed validity, and Cronbach’s alpha coefficient and intraclass correlation coefficient (ICC) were used for reliability. Results: The interitem correlation analyses revealed that 5 items were redundant; thus, the scale was reduced to 5 items. A 1-factor model explained 76.85% of the variance; confirmatory factor analysis showed that this model adequately fit the data. The ICC for test-retest reliability was .78; Cronbach’s alpha was .92. The PTES-K showed significant associations with the scores of diabetes self-care activities for physical activity, quality of life, and depressive symptoms. Participants with good glycemic control and regular physical activity tended to have a higher score on the PTES-K than their counterparts, demonstrating known-groups validity. Conclusions: The cross-cultural applicability, reliability, and validity of the PTES-K were confirmed. The PTES-K may be used in clinical settings to examine the potential role of perceived therapeutic efficacy for physical activity in enhanced glycemic control among patients with diabetes.

scholarly journals Budget Impact Analysis of Metformin Sustained Release for the Treatment of Type 2 Diabetes in The Netherlands

2019 ◽  
Vol 4 (2) ◽  
pp. 321-330 ◽  
Author(s):  
Judith J. Gout-Zwart ◽  
Lisa A. de Jong ◽  
Lisanne Saptenno ◽  
Maarten J. Postma
Keyword(s):  
Type 2 Diabetes ◽  
The Netherlands ◽  
Sustained Release ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis

scholarly journals The Impacts ofSLC22A1rs594709 andSLC47A1rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Di Xiao ◽  
Yu Guo ◽  
Xi Li ◽  
Ji-Ye Yin ◽  
Wei Zheng ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Therapeutic Efficacy ◽  
Healthy Subjects ◽  
Allele Frequencies ◽  
Metformin Treatment ◽  
Newly Diagnosed ◽  
Genotype Frequencies ◽  
Metformin Monotherapy ◽  
Significant Difference

Background. We aimed to investigate the distributive characteristics ofSLC22A1rs594709 andSLC47A1rs2289669 polymorphisms and their influence on metformin efficacy in Chinese T2DM patients.Methods. The distributions ofSLC22A1rs594709 andSLC47A1rs2289669 polymorphisms were determined in 267 T2DM patients and 182 healthy subjects. Subsequently, 53 newly diagnosed patients who received metformin monotherapy were recruited to evaluate metformin efficacy.Results. No significant difference was found between T2DM patients and healthy subjects inSLC22A1rs594709 andSLC47A1rs2289669 allele frequencies and genotype frequencies. After metformin treatment,SLC22A1rs594709 GG genotype patients showed a higher increase in FINS (p=0.015) and decrease in HOMA-IS (p=0.001) and QUICKI (p=0.002) than A allele carriers.SLC47A1rs2289669 GG genotype patients had a higher decrease in TChol (p=0.030) and LDL-C (p=0.049) than A allele carriers. AmongSLC22A1rs594709 AA genotype, patients withSLC47A1rs2289669 AA genotype showed a higher decrease in FBG (p=0.015), PINS (p=0.041), and HOMA-IR (p=0.014) than G allele carriers. However, amongSLC22A1rs594709 G allele carriers,SLC47A1rs2289669 AA genotype patients showed a higher decrease in TChol (p=0.013) than G allele carriers.Conclusion. Our data suggest thatSLC22A1rs594709 andSLC47A1rs2289669 polymorphisms may influence metformin efficacy together in Chinese T2DM patients.

scholarly journals Psychometric Properties of the Chinese Version of the Perceived Therapeutic Efficacy Scale for Type 2 Diabetes

2008 ◽  
Vol 107 (3) ◽  
pp. 232-238 ◽  
Author(s):  
Shu-Fang Vivienne Wu ◽  
Mary Courtney ◽  
Helen Edwards ◽  
Jan McDowell ◽  
Lillie M. Shortridge-Baggett ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Psychometric Properties ◽  
Therapeutic Efficacy ◽  
Chinese Version

scholarly journals Therapeutic efficacy of umbilical cord-derived mesenchymal stem cells in patients with type 2 diabetes

2015 ◽  
Vol 9 (5) ◽  
pp. 1623-1630 ◽  
Author(s):  
LI-XUE GUAN ◽  
HUI GUAN ◽  
HAI-BO LI ◽  
CUI-AI REN ◽  
LIN LIU ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Umbilical Cord ◽  
Therapeutic Efficacy
Sign in / Sign up

Export Citation Format

Share Document